AI Terminal
Spexis AG
Report Publication Announcement • Jul 20, 2022
957_rns_2022-07-20_92ad8e0d-b45e-40ba-901d-d4398314a35c.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
News Details
Corporate | 20 July 2022 07:30
Spexis announces business update call to be held on July 28th
Spexis AG / Key word(s): Conference
Spexis announces business update call to be held on July 28th
20.07.2022 / 07:30
Allschwil, Switzerland, July 20, 2022
Spexis announces business update call to be held on July 28 th
- **Conference call scheduled for Thursday, July 28, 2022, at 8 AM EDT / 2 PM CET****
Spexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a business update call on Thursday, July 28, 2022, at 8 AM EDT / 2 PM CET.
To participate, please use the following numbers:
France: +33 (0)1 70 730 3 39
Germany: +49 (0)69 22222 5197
Italy: +39 0200638217
Switzerland: +41 (0)44 580 7279
United Kingdom +44 (0)330 165 4012
United States +1 646-828-8075
Please dial in approximately 10 minutes prior to the start of the call. When asked, please provide the name of the event – “Spexis AG – Business and Strategy Update” – and the following confirmation code: 1507661.
The presentation will also be available via webcast:
- For participants of the conference call: https://www.webcast-eqs.com/spexis20220728/ no-audio ( audio via phone, presentation on the web browser)
- Live stream: https://www.webcast-eqs.com/spexis20220728 ( audio and presentation on the web browser; for passive participants)
A replay of the call will be available on the Company’s website in the Investor Relations – Calendar section here or via the above link.
For further information, please contact:
| For Investors: Hernan Levett Chief Financial Officer Spexis AG. +41 61 567 16 00 [email protected] Raimund Gabriel MC Services [email protected] Ph: +49 89 210 228 0 |
For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 92 56 [email protected] Dr. Brigitte Keller/Laurie Doyle MC Services [email protected] Europe: +49 89 210 228 0 U.S.: +1 339 832 0752 |
About Spexis
Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. For further information, please visit: www.spexisbio.com .
Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only as of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
End of Media Release
| Language: | English |
| Company: | Spexis AG |
| Hegenheimermattweg 125 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | +41 61 567 1600 |
| Fax: | +41 61 567 1601 |
| E-mail: | [email protected] |
| Internet: | www.spexisbio.com |
| ISIN: | CH0106213793 |
| Valor: | SPEX |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1401323 |
| End of News | EQS News Service |